Clinical Trials

The phase 1 INSIGHT-005 trial will further evaluate the combination of eftilagimod alpha and avelumab in patients with metastatic urothelial cancer.

A phase 1 trial evaluating 5-aminolevulinic acid and CV01 delivery of ultrasound has begun treating the first 3 of approximately 33 patients with recurrent high-grade glioma.

Part 2 of the NOVA-II phase 2 trial evaluating OQL011 has enrolled the first patient with cancer with VEGFR inhibitor-associated hand-foot skin reaction.

The newly launched phase 2 LenCabo study of lenvatinib with everolimus vs cabozantinib for the second- or third-line treatment of metastatic renal cell carcinoma.

A phase 1/2 clinical trial evaluating treatment with MRT-2359 in MYC-driven solid tumors has dosed its first patient and looks to improve early signals of clinical activity.

Following positive results and FDA action on pidnarulex in BRAC 1/2-positive ovarian cancer, a phase 1 study is exploring the agent in metastatic castration-resistant prostate cancer, in combination with talazoparib.

A phase 1/2 study of ZN-c3, encorafenib, and cetuximab in patients with BRAF V600E-mutated colorectal cancer will begin, led by Zentalis Pharmaceuticals and Pfizer.

With all patients with solid tumors enrolled in the phase 1 study of QBS72S, 2 more studies evaluating the agent in brain malignancies will commence.

A suspected unexpected serious adverse reaction to seclidemstat led the developer to pause a phase 1/2 evaluating the agent in patients with Ewing and FET-rearranged sarcoma.

The phase 2 DeFianCe study will evaluate the safety and efficacy of DKN-01 combined with bevacizumab and chemotherapy in patients with colorectal cancer vs becazixumab and chemotherapy alone.

As part of the phase 2 INSIGhT trial, VBI Vaccines, Inc, and Agenus will examine the combination of VBI-1901 and balstilimab in patients with glioblastoma.

The first of 160 patients with gastric or gastroesophageal junction cancer has been recruited for the phase 2 DisTinGuish study. Thirty-two study locations are actively recruiting more patients.

The PRESERVE 2 trial evaluating trilaciclib in patients with metastatic breast cancer has finished enrolling patients. Results from the interim analysis of the trial is expected in the second half of 2023.

Considering the potential to fill a treatment gap in the KRAS G12C-mutant non–small cell lung cancer population, the FDA has granted a fast track designation to the combination of BBP-398 and sotorasib.

Twelve-week safety data from the phase 2 ENVASARC trial of envafolimab alone and in combination with ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma support proceeding with enrollment of patients in the trial.

The phase 1/2 clinical trial of MB-106 is demonstrating high efficacy, durable responses, and a favorable safety profile as the first patient treated did not experience cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome

Following positive data examining ABC008 for inclusion body myositis, a phase 1/2 trial has begun evaluating the agent in patients with T-cell large granular lymphocytic leukemia.

Exelixis, Inc has expanded their clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the novel triplet of nivolumab, relatlimab, and XL092 in the phase 1b STELLAR-002 trial.

To determine the effectiveness of nirogacestat at 150mg twice a day in patients with ovarian granulosa cell tumors, the agent has been administered to the first patient in a phase 2 trial.

Enrollment has begun in the phase 1b trial examining PY159 alone and in combination with pembrolizumab in patients with unresectable and/or metastatic solid tumors that are refractory or relapsed to standard of care.

Following reports of durable response in a phase 1 study, the combination of onvansertib FOLFIRI, and bevacizumab will be evaluating in a phase 2 study of patients with metastatic colorectal cancer.

A patient enrolled in the phase 1 NADOM trial of darovasertib alone in non-metastatic uveal melanoma shows early signs of clinical efficacy.

Treatment with AST-301 will be explored in patients with HER2-low breast cancer in the phase 2 Cornerstone-011 study.

Enrollment has begun for a phase 2 study of a polarized dendritic cell vaccine plus interferon alpha-2b, rintatolimod, and celecoxib in melanoma with PD1/PD-L1-resistance.

The targeted alpha therapy, FPI-1966, has been dosed for the first time in a phase 1/2 study of patients with advanced solid tumors that express FGFR3.

An investigational new drug application has been accepted by the FDA allowing for the start of a phase 1 trial to evaluate the tolerability of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies

A study of real-world outcomes of patient with relapsed or refractory multiple myeloma treated with isatuximab in now enrolling.

Following promising preclinical data, the phase 1 IMproveMF trial in myelofibrosis doses its first patient with imetelstat and ruxolitinib.

Certain patients with Wilm's tumor-expressing solid tumors are eligible to be treated with an investigational agent in a phase 1 clinical trial.